Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2022 / 06:30PM GMT
Release Date Price: MXN931.97
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce our guest today, Emil Kakkis, the CEO of Ultragenyx. Thanks a lot for joining us today, Emil.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks for having me, Maury.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're going to do a fireside chat discussion. So for those who may be new to the story, can you provide a 1-minute overview of Ultragenyx, your commercial products and your pipeline?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Yes. Ultragenyx is a rare -- a company focused on rare and ultra-rare disease, has been in business 12 years. We're a commercial company with 4 approved products that we're commercializing in the U.S., Canada, Latin America, Europe and, most recently, beginning in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot